Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (6929)	8/12/1998 5:23:00 PM
From: StockDoc	Read Replies (2) \| Respond to of 17367

You are right, meningo is sepsis. Sepsis, in a certain sense, is like cancer. A drug that works in lymphoma does not necessarily work in colon cancer. Accordingly, I don't speculate on off-label use. Moreover, insurance companies will also need evidence that the drug works in, e.g., multiresistant Staphylococcus sepsis, to cover expenses. I speculate, however, that approval will approximately double the share price, at least for a while. It would be nice to catch it. When do we expect NDA review and advisory panel meeting?